乳癌治療のグローバル市場：画期的新薬の発見と商用化...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Executive Summary 4
2.1 Exceptionally Large and Innovative Pipeline 4
2.2 Alignment of First-in-Class Molecular Target with Disease Causation 4
2.3 A Highly Active Deals Landscape with Numerous Investment Opportunities 4

3 The Case for Innovation in the Breast Cancer Market 5
3.1 Growing Opportunities for Biologic Products 5
3.2 Diversification of Molecular Targets 5
3.3 Innovative First-in-Class Product Developments Remain Attractive 5
3.4 Changes in the Clinical and Commercial Environment to be More Favorable to Products Targeting Niche Patient Populations and Indications 6
3.5 Sustained Innovation 6
3.6 Report Guidance 6

4 Clinical and Commercial Landscape 8
4.1 Disease Overview 8
4.2 Disease Symptoms 8
4.3 Etiology 8
4.4 Pathophysiology 9
4.4.1 Tumor Initiation, and Aberrant Cell Proliferation and Survival 10
4.4.2 Tumor Metabolic Shift 11
4.4.3 Tumor Progression, Microenvironment Alteration and Angiogenesis 11
4.4.4 Cancer Stem Cells 12
4.5 Diagnosis 13
4.6 Prognosis and Disease Staging 13
4.6.1 Classification 14
4.7 Introduction to Breast Cancer Treatments 15
4.8 Surgery and Radiation Therapy 16
4.9 Overview of Marketed Products for Breast Cancer 16
4.9.1 Chemotherapy 17
4.9.2 Efficacy of Chemotherapy Regimens 18
4.9.3 Hormonal Therapies 20
4.9.4 Efficacy of Endocrine Therapies 20
4.9.5 Targeted Therapies 22
4.9.6 Efficacy of Targeted Therapies 23
4.10 Treatment Guidelines 26
4.11 Current Unmet Need in the Breast Cancer Market 29

5 Assessment of Pipeline Product Innovation 31
5.1 Breast Cancer Pipeline by Phase, Molecule Type and Molecular Target 31
5.2 First-in-Class Pipeline Programs 35

6 Signaling Network, Disease Causation and Innovation Alignment 40
6.1 The complexity of signaling networks in oncology 40
6.2 Signaling pathways, disease-causing mutations and first-in-class molecular target integration 41
6.3 First-in-Class Target Matrix Assessment 43

7 First-In-Class Target Evaluation 46
7.1 Pipeline Programs which Target Protein Kinase C Delta 46
7.2 Pipeline Programs which Target p53 47
7.3 Pipeline Programs which Target FGFR4 50
7.4 Pipeline Programs which Target Akt 1, 2 and 3 51
7.5 Pipeline Programs which Target HER3 54
7.6 Pipeline Programs which Target PI3K 56
7.7 Pipeline Programs which Target Murine Double Minute 2 58
7.8 Pipeline Programs which Target Growth factor receptor-bound protein 2 60
7.9 Pipeline Programs which Target Notch-1 61
7.10 Pipeline Programs which Target Signal Transducer and Activator of Transcription 3 63
7.11 Pipeline Programs which Target Cluster of Differentiation 44 65
7.12 Pipeline Programs which Target Protein Phosphatase 2A 66
7.13 Pipeline Programs which Target Heat Shock Protein 90 68
7.14 Pipeline Programs which Target Basigin (CD147) 70
7.15 Pipeline Programs which Target Rho-associated, Coiled-coil-containing Protein Kinase 1 71
7.16 Pipeline Programs which Target Creb 73
7.17 Pipeline Programs which Target Cyclin-Dependent Kinase 4 and Cyclin-Dependent Kinase 6 74
7.18 Pipeline Programs which Target Integrin αV 77
7.19 Conclusion 79

8 Deals and Strategic Consolidations 81
8.1 Licensing Deals 81
8.1.1 Molecule Type 84
8.1.2 Mechanism of Action 86
8.2 Co-Development Deals 92
8.2.1 Molecule Type 94
8.2.2 Mechanism of Action 96
8.3 First-In-Class Molecules not Involved in Licensing or Co-Development Deals 100

9 Appendix 103
9.1 Abbreviations 103
9.2 References 103
9.3 References for Heat Map 115
9.4 Contact Us 116
9.5 Disclaimer 116